nach oben

Tumor Biology

Erschienen in:

05.08.2015 | Original Article

Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B

verfasst von: Fardous F. El-Senduny, Farid A. Badria, Ahmed M. EL-Waseef, Subhash C. Chauhan, Fathi Halaweish

Erschienen in: Tumor Biology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Ovarian cancer is the most deadly gynecological cancer. The first line in treatment is platinum-based drugs. However, most patients suffer from tumor recurrence, characterized by resistance to cisplatin. A plausible approach to address the tumor resistance is to co-administer the chemotherapeutic agents along with natural products to offer a synergistic effect and optimize the dosage regimen. Cucurbitacin B is a natural product and displays antitumor activity against a wide array of cancer cell lines. The aim of this work is to determine the antitumor activity against ovarian cancer cell line (A2780) and possible sensitization activity on cisplatin-resistant cell line (A2780CP) in 2D and 3D culture model. 3D spheroids were generated from A2780CP cell line. A2780, A2780CP, and the spheroids were treated with cucurbitacin B, cisplatin alone, or pretreated with cucurbitacin B followed by cisplatin. The viability, cell cycle, and apoptosis were analyzed. Level of ROS and total glutathione was measured. In this study, cucurbitacin B showed cytotoxicity against the ovarian cancer cell lines, and pretreatment of A2780CP cells leads to a significant increase in the cytotoxicity of cisplatin. The mechanism behind the sensitization effect was dependent in part on the depletion of the total glutathione, an increase in ROS through a decrease in the level of dual-specificity tyrosine-regulated kinase (Dyrk1B), decrease in pERK1/2 and pSTAT3 level. The viability of spheroids treated with a combination of cisplatin and cucurbitacin B were significantly decreased. The resulting data shows that cucurbitacin B is a promising chemosensitizer for the cisplatin-resistant ovarian cancer.

Nur mit Berechtigung zugänglich

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.CrossRefPubMed

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49. doi:10.3322/caac.20006.CrossRefPubMed

Iwanicki MP, Davidowitz RA, Ng MR, Besser A, Muranen T, Merritt M, et al. Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov. 2011;1(2):144–57. doi:10.1158/2159-8274.cd-11-0010.CrossRefPubMedPubMedCentral

Nederman T, Acker H, Carlsson J. Penetration of substances into tumor tissue: a methodological study with microelectrodes and cellular spheroids. In Vitro. 1983;19(6):479–88.CrossRefPubMed

Rebucci M, Michiels C. Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol. 2013;85(9):1219–26. doi:10.1016/j.bcp.2013.02.017.CrossRefPubMed

Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol. 2007;63(1):12–31. doi:10.1016/j.critrevonc.2007.02.001.CrossRefPubMed

Mercurio F, Manning AM. Multiple signals converging on NF-kappaB. Curr Opin Cell Biol. 1999;11(2):226–32.CrossRefPubMed

Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol. 2002;3(3):221–7. doi:10.1038/ni0302-221.CrossRefPubMed

Hua Y, Jove R. The STATs of cancer—new molecular targets come of age. Nat Rev Cancer. 2004;4(2):97–105. doi:10.1038/nrc1275.CrossRef

10.

Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene. 2005;24(6):1053–65. doi:10.1038/sj.onc.1208298.CrossRefPubMed

11.

Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res. 2006;12(17):5055–63. doi:10.1158/1078-0432.ccr-06-0861.CrossRefPubMed

12.

Han Z, Feng J, Hong Z, Chen L, Li W, Liao S, et al. Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells. Biochem Biophys Res Commun. 2013;435(2):188–94. doi:10.1016/j.bbrc.2013.04.087.CrossRefPubMed

13.

Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood. 2003;101(12):4667–79. doi:10.1182/blood-2002-12-3647.CrossRefPubMed

14.

Lu Z, Xu S. ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life. 2006;58(11):621–31. doi:10.1080/15216540600957438.CrossRefPubMed

15.

Kim KY, Choi KC, Park SH, Auersperg N, Leung PC. Extracellular signal-regulated protein kinase, but not c-Jun N-terminal kinase, is activated by type II gonadotropin-releasing hormone involved in the inhibition of ovarian cancer cell proliferation. J Clin Endocrinol Metab. 2005;90(3):1670–7. doi:10.1210/jc.2004-1636.CrossRefPubMed

16.

Hayakawa J, Ohmichi M, Kurachi H, Ikegami H, Kimura A, Matsuoka T, et al. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem. 1999;274(44):31648–54.CrossRefPubMed

17.

Wulfkuhle JD, Aquino JA, Calvert VS, Fishman DA, Coukos G, Liotta LA, et al. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics. 2003;3(11):2085–90. doi:10.1002/pmic.200300591.CrossRefPubMed

18.

Bast Jr RC. Molecular approaches to personalizing management of ovarian cancer. Ann Oncol. 2011;22 Suppl 8:viii5–viii15. doi:10.1093/annonc/mdr516.CrossRefPubMedPubMedCentral

19.

Hu J, Friedman E. Depleting mirk kinase increases cisplatin toxicity in ovarian cancer cells. Genes Cancer. 2010;1(8):803–11. doi:10.1177/1947601910377644.CrossRefPubMedPubMedCentral

20.

Lai GM, Ozols RF, Young RC, Hamilton TC. Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. J Natl Cancer Inst. 1989;81(7):535–9.CrossRefPubMed

21.

Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 1993;75(2):241–51.CrossRefPubMed

22.

Chen X, Bao J, Guo J, Ding Q, Lu J, Huang M, et al. Biological activities and potential molecular targets of cucurbitacins: a focus on cancer. Anticancer Drugs. 2012;23(8):777–87. doi:10.1097/CAD.0b013e3283541384.CrossRefPubMed

23.

Alghasham AA. Cucurbitacins - a promising target for cancer therapy. Int J Health Sci. 2013;7(1):77–89.CrossRef

24.

Chen JC, Chiu MH, Nie RL, Cordell GA, Qiu SX. Cucurbitacins and cucurbitane glycosides: structures and biological activities. Nat Prod Rep. 2005;22(3):386–99. doi:10.1039/b418841c.CrossRefPubMed

25.

Chen W, Leiter A, Yin D, Meiring M, Louw VJ, Koeffler HP. Cucurbitacin B inhibits growth, arrests the cell cycle, and potentiates antiproliferative efficacy of cisplatin in cutaneous squamous cell carcinoma cell lines. Int J Oncol. 2010;37(3):737–43.PubMed

26.

Iwanski GB, Lee DH, En-Gal S, Doan NB, Castor B, Vogt M, et al. Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. Br J Pharmacol. 2010;160(4):998–1007. doi:10.1111/j.1476-5381.2010.00741.x.CrossRefPubMedPubMedCentral

27.

Lee DH, Thoennissen NH, Goff C, Iwanski GB, Forscher C, Doan NB, et al. Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma. Cancer Lett. 2011;306(2):161–70. doi:10.1016/j.canlet.2011.03.001.CrossRefPubMedPubMedCentral

28.

Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA. Spheroid-based drug screen: considerations and practical approach. Nat Protoc. 2009;4(3):309–24. doi:10.1038/nprot.2008.226.CrossRefPubMed

29.

Tung YC, Hsiao AY, Allen SG, Torisawa YS, Ho M, Takayama S. High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array. Analyst. 2011;136(3):473–8. doi:10.1039/c0an00609b.CrossRefPubMed

30.

Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF, Hamilton TC. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res. 1993;53(21):5225–32.PubMed

31.

Bartalis J, Halaweish FT. In vitro and QSAR studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines. Bioorg Med Chem. 2011;19(8):2757–66. doi:10.1016/j.bmc.2011.01.037.CrossRefPubMed

32.

Alfadda AA, Sallam RM. Reactive oxygen species in health and disease. J Biomed Biotechnol. 2012;2012:936486. doi:10.1155/2012/936486.CrossRefPubMedPubMedCentral

33.

Chou TC, Martin N. CompuSyn for drug combinations: PC software and user’s guide: a computer program for quantitation of synergism and antagonism in drug combinations, and the determination of IC50 and ED50 and LD50 Values, ComboSyn Inc, Paramus, (NJ), 2005.

34.

Tait SWG, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11(9):621–32. doi:10.1038/nrm2952.CrossRefPubMed

35.

Tan L, Kwok RP, Shukla A, Kshirsagar M, Zhao L, Opipari Jr AW, et al. Trichostatin A restores Apaf-1 function in chemoresistant ovarian cancer cells. Cancer. 2011;117(4):784–94. doi:10.1002/cncr.25649.CrossRefPubMed

36.

Shen M, Feng Y, Gao C, Tao D, Hu J, Reed E, et al. Detection of Cyclin B1 Expression in G1-phase cancer cell lines and cancer tissues by postsorting western blot analysis. Cancer Res. 2004;64(5):1607–10. doi:10.1158/0008-5472.can-03-3321.CrossRefPubMed

37.

Zheng H, Hu W, Deavers MT, Shen D-Y, Fu S, Li Y-F, et al. Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer. Am J Obstet Gynecol. 2009;201(4):367.e1-.e6. doi:10.1016/j.ajog.2009.05.021.CrossRef

38.

Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999;18(49):6853–66. doi:10.1038/sj.onc.1203239.CrossRefPubMed

39.

Wang CY, Cusack Jr JC, Liu R, Baldwin Jr AS. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med. 1999;5(4):412–7. doi:10.1038/7410.CrossRefPubMed

40.

Annunziata CM, Stavnes HT, Kleinberg L, Berner A, Hernandez LF, Birrer MJ, et al. Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer. 2010;116(13):3276–84. doi:10.1002/cncr.25190.CrossRefPubMedPubMedCentral

41.

Jin HR, Jin X, Dat NT, Lee JJ. Cucurbitacin B suppresses the transactivation activity of RelA/p65. J Cell Biochem. 2011;112(6):1643–50. doi:10.1002/jcb.23078.CrossRefPubMed

42.

Chan KT, Li K, Liu SL, Chu KH, Toh M, Xie WD. Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562. Cancer Lett. 2010;289(1):46–52. doi:10.1016/j.canlet.2009.07.015.CrossRefPubMed

43.

Chan KT, Meng FY, Li Q, Ho CY, Lam TS, To Y, et al. Cucurbitacin B induces apoptosis and S phase cell cycle arrest in BEL-7402 human hepatocellular carcinoma cells and is effective via oral administration. Cancer Lett. 2010;294(1):118–24. doi:10.1016/j.canlet.2010.01.029.CrossRefPubMed

44.

Duangmano S, Sae-Lim P, Suksamrarn A, Patmasiriwat P, Domann FE. Cucurbitacin B causes increased radiation sensitivity of human breast cancer Cells via G2/M Cell Cycle Arrest. J Oncol. 2012;2012:601682. doi:10.1155/2012/601682.CrossRefPubMedPubMedCentral

45.

Liu T, Peng H, Zhang M, Deng Y, Wu Z. Cucurbitacin B, a small molecule inhibitor of the Stat3 signaling pathway, enhances the chemosensitivity of laryngeal squamous cell carcinoma cells to cisplatin. Eur J Pharmacol. 2010;641(1):15–22. doi:10.1016/j.ejphar.2010.04.062.CrossRefPubMed

46.

Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific Proteolytic Cleavage of Poly(ADP-ribose) Polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 1993;53(17):3976–85.PubMed

47.

Dantzer F, de la Rubia G, Ménissier-de Murcia J, Hostomsky Z, de Murcia G, Schreiber V. Base excision repair is impaired in mammalian cells lacking poly(adp-ribose) polymerase-1†. Biochemistry. 2000;39(25):7559–69. doi:10.1021/bi0003442.CrossRefPubMed

48.

Bowman KJ, Newell DR, Calvert AH, Curtin NJ. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer. 2001;84(1):106.CrossRefPubMedPubMedCentral

49.

Godoy H, Mhawech-Fauceglia P, Beck A, Miller A, Lele S, Odunsi K. Expression of poly (adenosine diphosphate-ribose) polymerase and p53 in epithelial ovarian cancer and their role in prognosis and disease outcome. Int J Gynecol Pathol: Off J Int Soc Gynecol Pathol. 2011;30(2):139–44. doi:10.1097/PGP.0b013e3181fa5a64.CrossRef

50.

Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res. 2013;73(7):2271–80. doi:10.1158/0008-5472.CAN-12-3000.CrossRefPubMed

51.

Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A. 1992;89(7):3070–4.CrossRefPubMedPubMedCentral

52.

Gamcsik MP, Kasibhatla MS, Teeter SD, Colvin OM. Glutathione levels in human tumors. Biomarkers. 2012;17(8):671–91. doi:10.3109/1354750X.2012.715672.CrossRefPubMedPubMedCentral

53.

Andrews PA, Schiefer MA, Murphy MP, Howell SB. Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion. Chem Biol Interact. 1988;65(1):51–8.CrossRefPubMed

54.

Kausar H, Munagala R, Bansal SS, Aqil F, Vadhanam MV, Gupta RC. Cucurbitacin B potently suppresses non-small-cell lung cancer growth: identification of intracellular thiols as critical targets. Cancer Lett. 2013;332(1):35–45. doi:10.1016/j.canlet.2013.01.008.CrossRefPubMed

55.

Burleson K, Hansen L, Skubitz A. Ovarian carcinoma spheroids disseminate on type I collagen and invade live human mesothelial cell monolayers. Clin Exp Metastasis. 2005;21:685-697.

56.

Durand R, Sutherland R. Effects of intercellular contact on repair of radiation damage. Exp Cell Res. 1972;71:75–80.CrossRefPubMed

57.

Filipovich I, Sorokina N, Robillard N, Chatal J. Radiation-induced apoptosis in human ovarian carcinoma cells growing as a monolayer and as multicell spheroids. Int J Cancer. 1997;72:851–9.CrossRef

58.

Graham C, Kobayashi H, Stankiewicz K, Man S, Kapitain S, Kerbel R. Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents. J Natl Cancer Inst. 1994;86:975–82.CrossRefPubMed

59.

Makhija S, Taylor D, Gibb R, Gercel-Taylor. Taxol-induced Bcl-2 phosphorylation in ovarian cancer cell monolayer and spheroids. Int J Oncol. 1999;14:515–21.PubMed

60.

Bardies M, Thedrez P, Gestin J, Marcille B, Guerreau D, Faivre-Chauvet A, et al. Use of multi-cell spheroids of ovarian carcinoma as an intraperitoneal radio-immunotherapy model: uptake, retention kinetics and dosimetric evaluation. Int J Cancer. 1992;50:984–91.CrossRefPubMed

61.

Sutherland R, MacDonald H, Howell R. Multicellular spheroids: a new model target for in vitro studies of immunity to solid tumor allografts. J Natl Cancer Inst. 1977;58:1849–53.CrossRefPubMed

62.

Sutherland R, McCredie J, Inch W. Growth of multicell spheroids in tissue culture as a model of nodular carcinoma. J Natl Cancer Inst. 1971;46:113–20.PubMed

Titel: Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B
verfasst von: Fardous F. El-Senduny
Farid A. Badria
Ahmed M. EL-Waseef
Subhash C. Chauhan
Fathi Halaweish
Publikationsdatum: 05.08.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 1/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3773-8

Springer Medizin

Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

GSTT1 and GSTM1 polymorphisms predict treatment outcome for breast cancer: a systematic review and meta-analysis

Staphylococcal enterotoxin B/texosomes as a candidate for breast cancer immunotherapy

Introducing differential expression of human heat shock protein 27 in hepatocellular carcinoma: moving toward identification of cancer biomarker

miR-20a enhances cisplatin resistance of human gastric cancer cell line by targeting NFKBIB

Hesperidin from Citrus seed induces human hepatocellular carcinoma HepG2 cell apoptosis via both mitochondrial and death receptor pathways

Bioinformatic analyses revealed underlying biological functions correlated with oxaliplatin responsiveness

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie